<DOC>
	<DOC>NCT02255513</DOC>
	<brief_summary>This study will examine the efficacy and safety of HLD200 (methylphenidate) in patients age 6-12 years with ADHD. This study has a 6-week dose optimization period followed by a one week double blind randomization assessment.</brief_summary>
	<brief_title>A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD</brief_title>
	<detailed_description>Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common childhood disorders and can continue through adolescence and adulthood. Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior and hyperactivity (over-activity). This multicenter study will utilize a 6-week open label, treatment optimization phase followed by a double-blind, placebo-controlled, 1-week randomized, parallel-group test period designed to assess the safety and efficacy of HLD200 treatment in pediatric subjects with ADHD.</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male and female children (612 years at study entry) Previous diagnosis of ADHD and confirmation using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINIKID) Able to swallow treatment capsules Available for entire study period Provision of informed consent (from the parent[s] and/or legal representative[s]) and assent (from the subject) Female subjects of childbearing potential (i.e., postmenarche) required to have a negative result on urine pregnancy test (and will be given specific instructions for avoiding pregnancy during trial). Any known history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, ophthalmologic disease Presence of any significant physical or organ abnormality Any illness during the 4 weeks before this study Comorbid psychiatric diagnosis that may affect subject safety or confound results (e.g., psychosis, bipolar disorder) Known history of severe asthma (in the opinion of the investigator) unless deemed currently controlled Known history of severe allergic reaction to MPH Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa, bulimia or current diagnosis or family history of Tourette's disorder Subject who are severely underweight or overweight (in the opinion of the Investigator) Any clinical laboratory value outside of the acceptable ranges, unless deemed NCS significant per the Investigator Positive history for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) Positive screening for illicit drug use, and/or current health conditions or use of medications that might confound the results of the study or increase risk to the subject Use of prescription medications (except ADHD medications) within 7 days and overthecounter medications (except birth control) within the 3 days preceding study enrollment, unless deemed acceptable by the Investigator and Clinical or Medical Monitor Participation in clinical trial with an investigational drug within the 30 days preceding study enrollment Current suicidal ideation or history of suicidality determined as a significant finding on the CSSRS by the investigator (Baseline CSSRS for adolescents; Pediatric Baseline CSSRS for children).</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>